Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014, China
Location status: Recruiting
Location contact
Huiyuan Wang
SUB_INVESTIGATOR
Sheng Zhang
CONTACT
Sheng Zhang
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06451887
To design and validate a predictive model for malignant brain edema after endovascular thrombectomy.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Hangzhou, Zhejiang, 310014, China
Location status: Recruiting
Huiyuan Wang
SUB_INVESTIGATOR
Sheng Zhang
CONTACT
Sheng Zhang
PRINCIPAL_INVESTIGATOR
Stroke is a significant global cause of death and disability. Endovascular thrombectomy (EVT) is currently the best treatment for acute large vessel occlusion stroke (ALVOS), as it can greatly reduce mortality and improve patient outcomes. However, only half of patients who undergo EVT achieve functional independence, and malignant brain edema (MBE), a severe complication, can occur after the procedure, leading to a poor prognosis. Previous studies have confirmed the effectiveness of early decompressive hemicraniectomy in reducing morbidity and mortality in patients with malignant brain edema. Therefore, identifying high-risk patients for MBE can help clinicians make appropriate triage and early intervention decisions, potentially saving patients' lives.
Predictive factors for post-ischemic stroke brain edema have been widely discussed, and reliable early predictive indicators have been identified, such as age, early consciousness disorders, baseline National Institutes of Health Stroke Scale (NIHSS), atrial fibrillation, hypertension, baseline blood glucose, and the level of reperfusion after EVT. Radiological factors, such as the Alberta Stroke Program Early CT Score (ASPECTS), collateral circulation rating of arteries, venous outflow status, CT perfusion core infarct volume, perfusion-based collateral status, and clot burden, are closely associated with the occurrence of MBE post-EVT. However, due to individual differences and multiple factors affecting MBE, a single factor cannot effectively predict MBE. Establishing a clinical risk prediction model can effectively identify high-risk populations for MBE at an early stage.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 days post-EVT
Patients developed MBE within 3 days post-EVT
Time frame: 90 days after EVT
The follow-up mRS scores of enrolled patients at 90 days after EVT.
Time frame: 3-5 days after EVT
Evidence of parenchymal hemorrhage (PH type) on cranial imaging at 3-5 days after EVT
Contact information is provided by the study sponsor or research team.
Zhejiang Provincial People's Hospital
Other
Acronym: EMBRACE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07347665
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Nishinomiya, Hyōgo, Japan
View Trial DetailsNCT07333950
Acute Basilar Artery Occlusion, Brain Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT07527013
Acute Ischaemic Stroke, Blood Pressure Management
Beijing, Beijing Municipality, China
View Trial DetailsNCT07304973
Endovascular Therapy, Neurological Complications
Chengdu, Sichuan, China
View Trial Details